Who are Xeloda's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, 5-Fluouracil, 5-Fluorouracile, Trifluridine and Tipiracil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/xeloda.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Xeloda — Competitive Intelligence Brief

Xeloda (Xeloda) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Xeloda (Xeloda) — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Xeloda TARGET	Xeloda	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	marketed		Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
5-Fluouracil	5-Fluouracil	Hoffmann-La Roche	marketed	Antimetabolite	Thymidylate synthase; RNA and DNA incorporation
5-Fluorouracile	5-Fluorouracile	Groupe Oncologie Radiotherapie Tete et Cou	marketed	Antimetabolite; pyrimidine analog	Thymidylate synthase; RNA and DNA incorporation
Trifluridine and Tipiracil	Trifluridine and Tipiracil	Amgen	marketed	Antimetabolite combination; thymidylate synthase inhibitor	Thymidylate synthase; thymidine phosphorylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xeloda — Competitive Intelligence Brief. https://druglandscape.com/ci/xeloda. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab